Abstract
Purpose
Colloids are administered to more patients than crystalloids, although recent evidence suggests that colloids may possibly be harmful in some patients. The European Society of Intensive Care Medicine therefore assembled a task force to compile consensus recommendations based on the current best evidence for the safety and efficacy of the currently most frequently used colloids—hydroxyethyl starches (HES), gelatins and human albumin.
Methods
Meta-analyses, systematic reviews and clinical studies of colloid use were evaluated for the treatment of volume depletion in mixed intensive care unit (ICU), cardiac surgery, head injury, sepsis and organ donor patients. Clinical endpoints included mortality, kidney function and bleeding. The relevance of concentration and dosage was also assessed. Publications from 1960 until May 2011 were included. The quality of available evidence and strength of recommendations were based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
Recommendations and conclusions
We recommend not to use HES with molecular weight ≥200 kDa and/or degree of substitution >0.4 in patients with severe sepsis or risk of acute kidney injury and suggest not to use 6% HES 130/0.4 or gelatin in these populations. We recommend not to use colloids in patients with head injury and not to administer gelatins and HES in organ donors. We suggest not to use hyperoncotic solutions for fluid resuscitation. We conclude and recommend that any new colloid should be introduced into clinical practice only after its patient-important safety parameters are established.
Similar content being viewed by others
Notes
Increased risk of AKI was defined by a recent consensus conference as advanced age, sepsis, cardiovascular surgery, contrast nephropathy [64].
References
Shafer SL (2010) Notice of retraction. Anesth Analg 111:1567
Shafer SL (2011) Shadow of doubt. Anesth Analg 112:498–500
Perel P, Roberts I (2011) Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 3:CD000567
Bunn F, Trivedi D, Ashraf S (2011) Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev 3:CD001319
Delaney AP, Dan A, McCaffrey J, Finfer S (2011) The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 39:386–391
Hartog CS, Kohl M, Reinhart K (2011) A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg 112:635–645
Reinhart K, Takala J (2011) Hydroxyethyl starches: what do we still know? Anesth Analg 112:507–511
Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, Du B, McArthur C, Myburgh J, Investigators TS (2010) Resuscitation fluid use in critically ill adults: an international cross sectional study in 391 intensive care units. Crit Care 14:R185
Schortgen F, Deye N, Brochard L (2004) Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med 30:2222–2229
[No authors listed] (2004) Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement. Am J Respir Crit Care Med 170:1247–1259
Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, Laghi F, Magder S, Papazian L, Pelosi P, Polderman KH (2010) An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med 181:1128–1155
Joannidis M, Druml W, Forni LG, Groeneveld AB, Honore P, Oudemans-van Straaten HM, Ronco C, Schetz MR, Woittiez AJ (2009) Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology. ESICM. Intensive Care Med 36:392–411
Powell-Tuck J, Gosling P, Lobo DN, Allison S, Carlson GL, Gore M, Lewington AJ, Pearse RM, Mythen MG (2008) British Consensus Guidelines on Intravenous Fluid Therapy for Adult Surgical Patients (GIFTASUP). 2008. London: NHS National Library of Health. Available at http://www.ics.ac.uk/downloads/2008112340_GIFTASUP%20FINAL_31-10-08.pdf
Liu B, Finfer S (2009) Intravenous fluids in adults undergoing surgery. BMJ 338:b2418
Dretzke J, Sandercock J, Bayliss S, Burls A (2004) Clinical effectiveness and cost-effectiveness of prehospital intravenous fluids in trauma patients. Health Technol Assess 8:iii, 1–103
Heier HE, Bugge W, Hjelmeland K, Soreide E, Sorlie D, Haheim LL (2006) Transfusion vs. alternative treatment modalities in acute bleeding: a systematic review. Acta Anaesthesiol Scand 50:920–931
Toomtong P, Suksompong S (2010) Intravenous fluids for abdominal aortic surgery. Cochrane Database Syst Rev: CD000991
Dart AB, Mutter TC, Ruth CA, Taback SP (2010) Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev: CD007594
Perel P, Roberts I (2009) Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev: CD000567
[No authors listed] (1998) Department of Health and Human Services, Food and Drug Administration, 21 CFR Part 216 [Docket No. 98N-0655] List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness. Federal Register: October 8, 1998 (Volume 63, Number 195) pages 54082-54089 Availabe via http://wwwfdagov/ohrms/dockets/98fr/100898btxt Assessed on 30 November 2010
[No authors listed] (1998) Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ 317:235–240
Alderson P, Bunn F, Lefebvre C, Li WP, Li L, Roberts I, Schierhout G (2002) Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev: CD001208
Wilkes MM, Navickis RJ (2001) Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 135:149–164
Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350:2247–2256
Alderson P, Bunn F, Lefebvre C, Li WP, Li L, Roberts I, Schierhout G (2004) Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev: CD001208
Vincent JL, Navickis RJ, Wilkes MM (2004) Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med 32:2029–2038
Vincent JL, Wilkes MM, Navickis RJ (2003) Safety of human albumin: serious adverse events reported worldwide in 1998–2000. Br J Anaesth 91:625–630
Barron ME, Wilkes MM, Navickis RJ (2004) A systematic review of the comparative safety of colloids. Arch Surg 139:552–563
Groeneveld AB, Navickis RJ, Wilkes MM (2011) Update on the comparative safety of colloids: a systematic review of clinical studies. Ann Surg 253:470–483
Zarychanski R, Turgeon AF, Fergusson DA, Cook DJ, Hebert P, Bagshaw SM, Monsour D, McIntyre LA (2009) Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med 3:E196–209
Davidson IJ (2006) Renal impact of fluid management with colloids: a comparative review. Eur J Anaesthesiol 23:721–738
Sakr Y, Payen D, Reinhart K, Sipmann FS, Zavala E, Bewley J, Marx G, Vincent JL (2007) Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 98:216–224
Akech S, Gwer S, Idro R, Fegan G, Eziefula AC, Newton CR, Levin M, Maitland K (2006) Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin Trials 1:e21
Finfer S, McEvoy S, Bellomo R, Liu B, McArthur C, Myburgh J, Norton R (2011) Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 37:86–96
Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, Nyeko R, Mtove G, Reyburn H, Lang T, Brent B, Evans JA, Tibenderana JK, Crawley J, Russell EC, Levin M, Babiker AG, Gibb DM (2011) Mortality after fluid bolus in African children with severe infection. N Engl J Med 364:2483–2495
Sedrakyan A, Gondek K, Paltiel D, Elefteriades JA (2003) Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. Chest 123:1853–1857
Russell JA, Navickis RJ, Wilkes MM (2004) Albumin versus crystalloid for pump priming in cardiac surgery: meta-analysis of controlled trials. J Cardiothorac Vasc Anesth 18:429–437
Myburgh J, Cooper DJ, Finfer S, Bellomo R, Norton R, Bishop N, Kai Lo S, Vallance S (2007) Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 357:874–884
Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139
Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L (2001) Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357:911–916
Wiedermann CJ (2008) Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 8:1
Schabinski F, Oishi J, Tuche F, Luy A, Sakr Y, Bredle D, Hartog C, Reinhart K (2009) Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients. Intensive Care Med 35:1539–1547
Bayer O, Reinhart K, Sakr Y, Kabisch B, Kohl M, Riedemann NC, Bauer M, Settmacher U, Hekmat K, Hartog CS (2011) Renal effects of synthetic colloids and crystalloids in patients with severe sepsis: a prospective sequential comparison. Crit Care Med 39:1335–1342
Wilkes MM, Navickis RJ, Sibbald WJ (2001) Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg 72:527–533
Moskowitz DM, Shander A, Javidroozi M, Klein JJ, Perelman SI, Nemeth J, Ergin MA (2008) Postoperative blood loss and transfusion associated with use of Hextend in cardiac surgery patients at a blood conservation center. Transfusion 48:768–775
Avorn J, Patel M, Levin R, Winkelmayer WC (2003) Hetastarch and bleeding complications after coronary artery surgery. Chest 124:1437–1442
Haynes GR, Havidich JE, Payne KJ (2004) Why the food and drug administration changed the warning label for hetastarch. Anesthesiology 101:560–561
Rioux JP, Lessard M, De Bortoli B, Roy P, Albert M, Verdant C, Madore F, Troyanov S (2009) Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery. Crit Care Med 37:1293–1298
Magder S, Potter BJ, Varennes BD, Doucette S, Fergusson D (2010) Fluids after cardiac surgery: a pilot study of the use of colloids versus crystalloids. Crit Care Med 38:2117–2124
Lissauer ME, Chi A, Kramer ME, Scalea TM, Johnson SB (2011) Association of 6% hetastarch resuscitation with adverse outcomes in critically ill trauma patients. Am J Surg 202(1):53–58
Tseng MY, Hutchinson PJ, Kirkpatrick PJ (2008) Effects of fluid therapy following aneurysmal subarachnoid haemorrhage: a prospective clinical study. Br J Neurosurg 22:257–268
Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R (2003) Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 96:1453–1459
Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P (1996) Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 348:1620–1622
Robert R, Guilhot J, Pinsard M, Longeard PL, Jacob JP, Gissot V, Hauet T, Seguin F (2011) A pair analysis of the delayed graft function in kidney recipient: the critical role of the donor. J Crit Care 25:582–590
Giral M, Bertola JP, Foucher Y, Villers D, Bironneau E, Blanloeil Y, Karam G, Daguin P, Lerat L, Soulillou JP (2007) Effect of brain-dead donor resuscitation on delayed graft function: results of a monocentric analysis. Transplantation 83:1174–1181
Hokema F, Ziganshyna S, Bartels M, Pietsch UC, Busch T, Jonas S, Kaisers U (2011) Is perioperative low molecular weight hydroxyethyl starch infusion a risk factor for delayed graft function in renal transplant recipients? Nephrol Dial Transplant 26(10):3373–3378
Deman A, Peeters P, Sennesael J (1999) Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicentre analysis. Nephrol Dial Transplant 14:1517–1520
Wu Y, Wu AS, Wang J, Tian M, Jia XY, Rui Y, Yue Y (2010) Effects of the novel 6% hydroxyethyl starch 130/0.4 on renal function of recipients in living-related kidney transplantation. Chin Med J (Engl) 123:3079–3083
Jacob M, Chappell D, Conzen P, Wilkes MM, Becker BF, Rehm M (2008) Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials. Crit Care 12:R34
Wiedermann CJ, Dunzendorfer S, Gaioni LU, Zaraca F, Joannidis M (2010) Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Crit Care 14:R191
Schortgen F, Girou E, Deye N, Brochard L (2008) The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 34:2157–2168
Autrat-Leca E, Jonville-Béra A, Paintaud G (1999) Commission de Pharmacovigilance de l’AFFSaPS: Décisions: La durée maximale de traitement par Elohes. Actualités en Pharmacologie Clinique 47 http://membres.lycos.fr/crpv/Avril-Juil%2099.pdf. Accessed Jan 2006
Thompson WL (1975) Rational use of albumin and plasma substitutes. Johns Hopkins Med J 136:220–225
Bork K (2005) Pruritus precipitated by hydroxyethyl starch: a review. Br J Dermatol 152:3–12
Arellano R, Gan BS, Salpeter MJ, Yeo E, McCluskey S, Pinto R, Irish J, Ross DC, Doyle DJ, Parkin J, Brown D, Rotstein L, Witterick I, Matthews W, Yoo J, Neligan PC, Gullane P, Lampe H (2005) A triple-blinded randomized trial comparing the hemostatic effects of large-dose 10% hydroxyethyl starch 264/0.45 versus 5% albumin during major reconstructive surgery. Anesth Analg 100:1846–1853
Jamal R, Ghannoum M, Naud J, Turgeon P, Leblan M (2008) Permanent renal failure induced by pentastarch. NDT Plus 1(5):322–325
Hagne C, Schwarz A, Gaspert A, Giambarba C, Keusch G (2009) HAES in septic shock—sword of Damocles? Schweiz Med Forum 9:304–306
Auwerda JJ, Leebeek FW, Wilson JH, van Diggelen OP, Lam KH, Sonneveld P (2006) Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch. Transfusion 46:1705–1711
Ginz HF, Gottschall V, Schwarzkopf G, Walter K (1998) Excessive tissue storage of colloids in the reticuloendothelial system. Anaesthesist 47:330–334
Schmidt-Hieber M, Loddenkemper C, Schwartz S, Arntz G, Thiel E, Notter M (2006) Hydrops lysosomalis generalisatus: an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol 77:83–85
Boussekey N, Darmon R, Langlois J, Alfandari S, Devos P, Meybeck A, Chiche A, Georges H, Leroy O (2010) Resuscitation with low volume hydroxyethylstarch 130 kDa/0.4 is not associated with acute kidney injury. Crit Care 14:R40
Kasper SM, Meinert P, Kampe S, Gorg C, Geisen C, Mehlhorn U, Diefenbach C (2003) Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology 99:42–47
[No authors listed] (2007) US Department of Health and Human Services, Public health service, Food and Drug Administration (FDA). NDA REVIEW MEMO (MID-CYCLE). Available via http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/NewDrugApplicationsNDAs/UCM083393.pdf. Accessed 20 Nov 2010
Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H (2009) Hydroxyethyl starches: different products—different effects. Anesthesiology 111:187–202
Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P (2008) The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg 107:382–390
Blasco V, Leone M, Antonini F, Geissler A, Albanese J, Martin C (2008) Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. Br J Anaesth 100:504–508
Gattas (2011) Fluid resuscitation with 6% hydroxyethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis. Anesth Analg (in press)
James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS (2011) Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). Br J Anaesth 107:693–702
James MFM, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS (2012) Re:Hydroxy ethyl starch in patients with trauma. E-Letter. BJA. http://bja.oxfordjournals.org/content/early/2011/08/19/bja.aer229.long/reply#brjana_el_7842. Accessed 25 Jan 2012
Nunnally ME, Jaeschke R, Bellingan GJ, Lacroix J, Mourvillier B, Rodriguez-Vega GM, Rubertsson S, Vassilakopoulos T, Weinert C, Zanotti-Cavazzoni S, Buchman TG (2011) Targeted temperature management in critical care: a report and recommendations from five professional societies. Crit Care Med 39:1113–1125
Velanovich V (1989) Crystalloid versus colloid fluid resuscitation: a meta-analysis of mortality. Surgery 105:65–71
Bisonni RS, Holtgrave DR, Lawler F, Marley DS (1991) Colloids versus crystalloids in fluid resuscitation: an analysis of randomized controlled trials. J Fam Pract 32:387–390
Schierhout G, Roberts I (1998) Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ 316:961–964
Himpe D (2003) Colloids versus crystalloids as priming solutions for cardiopulmonary bypass: a meta-analysis of prospective, randomised clinical trials. Acta Anaesthesiol Belg 54:207–215
Alderson P, Schierhout G, Roberts I, Bunn F (2000) Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev: CD000567
Roberts I, Alderson P, Bunn F, Chinnock P, Ker K, Schierhout G (2004) Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev: CD000567
Akech S, Ledermann H, Maitland K (2010) Choice of fluids for resuscitation in children with severe infection and shock: systematic review. BMJ 341:c4416
Choi PT, Yip G, Quinonez LG, Cook DJ (1999) Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 27:200–210
Cyna AM, Andrew M, Emmett RS, Middleton P, Simmons SW (2009) Techniques for preventing hypotension during spinal anaesthesia for caesarean section. Cochrane Database Syst Rev: CD002251
Bunn F, Trivedi D, Ashraf S (2008) Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev: CD001319
Liberati A, Moja L, Moschetti I, Gensini GF, Gusinu R (2006) Human albumin solution for resuscitation and volume expansion in critically ill patients. Intern Emerg Med 1:243–245
Bayer O, Reinhart K, Sakr Y, Kabisch B, Kohl M, Riedemann NC, Bauer M, Settmacher U, Hekmat K, Hartog CS (2011) Renal effects of synthetic colloids and crystalloids in patients with severe sepsis: a prospective sequential comparison. Crit Care Med 39(6):1335–1342
Gondos T, Marjanek Z, Ulakcsai Z, Szabo Z, Bogar L, Karolyi M, Gartner B, Kiss K, Havas A, Futo J (2010) Short-term effectiveness of different volume replacement therapies in postoperative hypovolaemic patients. Eur J Anaesthesiol 27:794–800
Hecht-Dolnik M, Barkan H, Taharka A, Loftus J (2009) Hetastarch increases the risk of bleeding complications in patients after off-pump coronary bypass surgery: a randomized clinical trial. J Thorac Cardiovasc Surg 138:703–711
van der Heijden M, Verheij J, van Nieuw Amerongen GP, Groeneveld AB (2009) Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia. Crit Care Med 37:1275–1281
Acknowledgments
Support was provided solely from institutional and/or departmental sources.
Conflicts of interest
C.L.S., R.J., F.S., A.B.J.G., R.B., and C.S.H. declare no conflict of interest. A.P. has received support for research from B. Braun Medical and Fresenius Kabi and honoraria from Ferring Pharmaceuticals. A.B.J.G. has received unrestricted research grants from B. Braun in the past. K.R. has received unrestricted research grant for the conduct of the VISEP trial and consultancy fees from B. Braun Melsungen.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Reinhart, K., Perner, A., Sprung, C.L. et al. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med 38, 368–383 (2012). https://doi.org/10.1007/s00134-012-2472-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-012-2472-9